Immune Design (IMDZ) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Immune Design (IMDZ) Files $250M Common Stock Shelf
August 12, 2015 4:31 PM EDTImmune Design (NASDAQ: IMDZ) filed a registration with the U.S. SEC to sell up to $250 million of its common stock.
... MoreImmune Design (IMDZ), Genentech (RHHBY) Enter Collaboration to Evaluate CMB305, MPDL3280A Combo
August 12, 2015 8:04 AM EDTImmune Design (NASDAQ: IMDZ) announced it has entered into a clinical trial collaboration with Genentech, a member of the Roche Group, to evaluate the safety and efficacy of Immune Design's CMB305 cancer immunotherapy product candidate combined with the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PDL1) in a... More
